ClinicalTrials.gg
Not yet recruitingNCT07943312Updated Nov 17, 2026

GA001 Injection in Retinitis Pigmentosa

A Phase 2 interventional study of GA001 and Sham injection in Retinitis Pigmentosa (RP), sponsored by GenAns Biotechnology Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by GenAns Biotechnology Co., Ltd · Phase 2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Retinitis Pigmentosa with a site in China — 13 open to participants now, 14 under way, 1 of them phase 3. Retinitis Pigmentosa · China.

Planned enrollment
12th of 16
12 · median 23
Started
2027
the only one that year
Phase 2
2 of 18
1 open now
Primary completion
2029-11
later than 12 of 13 live
Registered
18th of 18
by date
Lead sponsor
1 of 18
GenAns Biotechnology Co., Ltd

Among the 18 studies in Retinitis Pigmentosa with a site in China, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2027, is one of 2 in phase 2, reaches primary completion later than 12 of the 13 other live ones, and was the 18th registered.

Retinitis Pigmentosa

278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

13 of the 18 studies in Retinitis Pigmentosa with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Retinitis Pigmentosa with a site in China, or all of them as a file.
02

Study summary

This Phase II clinical trial evaluates the safety, tolerability, and efficacy of GA001 Injection in patients with retinitis pigmentosa.

Read the detailed description

Retinitis pigmentosa (RP) is an inherited retinal disease that causes gradual vision loss and can lead to blindness, with no approved curative treatment currently available.

This Phase II study is designed to evaluate the safety, tolerability, and efficacy of a single unilateral intravitreal injection of GA001 Injection at the target dose compared with sham injection in patients with retinitis pigmentosa. The study employs a sham-controlled design and will assess safety and efficacy outcomes as well as multiple functional and structural measures of visual performance over long-term follow-up.

03

Conditions studied

  • Retinitis Pigmentosa (RP)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18 to 70 years.
  2. Clinical diagnosis of advanced retinitis pigmentosa (RP).
  3. Best corrected visual acuity at or below the protocol-defined threshold in the study eye.
  4. Ability to understand and sign (and assent, when applicable).
  5. Laboratory test results are within the protocol-defined threshold range.

Exclusion criteria

Exclusion Criteria:

  1. Presence of other ocular conditions that could interfere with study assessments.
  2. History of significant ocular surgery in the study eye within a protocol-defined period.
  3. Active ocular infection or inflammation.
  4. systemic disease that could increase study risk or interfere with assessments.
  5. Positive screening for clinically significant infectious diseases, as defined in the protocol.
  6. Any condition that, in the investigator's judgment, would make the participant unsuitable for study participation.
  7. Pregnant or breastfeeding individuals.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    GA001

    Genetic: GA001

  • Sham comparator
    Sham Injection

    Procedure: Sham injection

Interventions

  • GeneticGA001

    Single unilateral IVT injection of GA001 Injection in the study eye

  • ProcedureSham injection

    Sham IVT procedure in the study eye

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of GA001 Injection in patients with retinitis pigmentosa

    BCVA-Change from Baseline in LogMAR Best Corrected Visual Acuity (BCVA) BCVA assessed by ETDRS charts at each post-treatment visit compared with the sham group.baseline→W52,Unit: LogMAR MLMT-Change from Baseline in Multi-Luminance Mobility Test (MLMT) Performance MLMT 7 levels; baseline→W52 ambient Lux to finish course, vs. sham. Unit: Lux Light Sensitivity-Change from Baseline in Light Sensitivity (Minimum Identifiable Brightness) Min brightness (Lux), study eye; baseline→W52, vs. sham. Unit: Lux FST Threshold-Change from Baseline in Full-Field Stimulus Test (FST) Threshold Full-field stimulus test; baseline→W52, vs. sham. Unit: log cd·s/m² Central Visual Field-Change from Baseline in Central Visual Field Static perimetry; baseline→W52, vs. sham. Unit: dB (mean deviation) MRDQ-Change from Baseline in Michigan Retinal Degeneration Questionnaire (MRDQ) Total Score MRDQ total score; baseline→W52, vs. sham. Unit: total score (points)

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events and serious adverse events

    Incidence of severity of ocular and systemic adverse events (AEs) and serious adverse events (SAEs) following a single intravitreal injection of GA001

    Time frame: Baseline to Week 52

  2. Evaluation of the Immunogenicity of GA001 Injection after a Single Intravitreal Administration in Patients with Retinitis Pigmentosa

    Immunogenicity of GA001 Injection will be evaluated following a single intravitreal injection in patients with retinitis pigmentosa, by AAV neutralizing antibody titers in peripheral blood (cell-based neutralizing assay) and by analysis of GA001-specific T-cell immune responses.

    Time frame: Baseline to Week 52

  3. Maximum Concentration (Cmax) of GA001 Vector DNA

    Cmax of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.

    Time frame: Baseline to Week 52

  4. Area Under the Concentration-Time Curve (AUC) of GA001 Vector DNA

    AUC of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.

    Time frame: Baseline to Week 52

  5. Time to Maximum Concentration (Tmax) of GA001 Vector DNA

    Tmax of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.

    Time frame: Baseline to Week 52

  6. Biodistribution of GA001 Vector DNA

    Biodistribution of GA001 vector DNA will be assessed by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.

    Time frame: Baseline to Week 52

  7. Shedding of GA001 Vector DNA

    Shedding of GA001 vector DNA will be assessed by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.

    Time frame: Baseline to Week 52

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2027; primary completion for Nov 2029, 31 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 17, 2026
StartEst.
Apr 1, 2027
Primary completionEst.
Nov 25, 2029
CompletionEst.
Nov 25, 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943312
Lead sponsor
GenAns Biotechnology Co., Ltd
Collaborators
Shanghai General Hospital, China
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Apr 1, 2027 (estimated)
Primary completion
Nov 25, 2029 (estimated)
Completion
Nov 25, 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Xiaodong Sun Principal Investigator, PhD
Contact
xdsun@sjtu.edu.cn
86 17853138155

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion